2025-06-25 01:59:38
Latest Post
Supreme Infrastructure India Ltd receives contract worth Rs. 450 crore
CarTrade Labs to Drive Innovation and Shape the Future of Technology
Solarium Green Energy Ltd receives order worth Rs. 35.32 crore
RITES Ltd receives LoI from Gujarat Urban Development Company Ltd
BLS E-Services subsidiary has signed definitive agreement to acquire CSPs of SBI & HDFC Bank
Stock Report
Alivus Life Sciences Ltd posts net profit of Rs. 141.86 crores in Q4FY25
Posted On : 2025-05-15 23:56:42( TIMEZONE : IST )
Glenmark Life Sciences Ltd has reported Standalone financial results for the period ended March 31, 2025.
Financial Results (Q4 FY2025) - QoQ Comparison
The company has reported total income of Rs. 659.633 crores during the period ended March 31, 2025 as compared to Rs. 652.30 crores during the period ended December 31, 2024.
The company has posted net profit / (loss) of Rs. 141.868 crores for the period ended March 31, 2025 as against net profit / (loss) of Rs. 136.960 crores for the period ended December 31, 2024.
The company has reported EPS of Rs. 11.55 for the period ended March 31, 2025 as compared to Rs. 11.14 for the period ended December 31, 2024.
| Financials | Q4 FY2025 | Q3 FY2025 | % Change |
| Total Income | ₹ 659.633 crs | ₹652.30 crs |  1.12% |
| Net Profit | ₹141.868 crs | ₹136.960 crs | 3.58% |
| EPS | ₹11.55 | ₹11.14 | 3.68% |
Financial Results (Q4 FY2025) - YoY Comparison
The company has reported total income of Rs. 659.633 crores during the period ended March 31, 2025 as compared to Rs.539.728 crores during the period ended March 31, 2024.
The company has posted net profit / (loss) of Rs.141.868 crores for the period ended March 31, 2025 as against net profit / (loss) of Rs.97.937 crores for the period ended March 31, 2024.
The company has reported EPS of Rs.11.55 for the period ended March 31, 2025 as compared to Rs.7.97 for the period ended March 31, 2024.
| Financials | Q4 FY2025 | Q4 FY2024 | % Change |
| Total Income | ₹ 659.633 crs | ₹539.728 crs | 22.22% |
| Net Profit | ₹141.868 crs | ₹97.937 crs | 44.86% |
| EPS | ₹11.55 | ₹7.97 | 44.92% |
Financial Results (Year Ended FY2025) - YoY Comparison
The company has reported total income of Rs.2421.454 crores during the Financial Year ended March 31, 2025 as compared to Rs.2295.256 crores during the Financial Year ended March 31, 2024.
The company has posted net profit / (loss) of Rs.485.627 crores for the Financial Year ended March 31, 2025 as against net profit / (loss) of Rs.470.888 crores for the Financial Year ended March 31, 2024.
The company has reported EPS of Rs.39.52 for the Financial Year ended March 31, 2025 as compared to Rs.38.38 for the Financial Year ended March 31, 2024.
| Financials | Year Ended FY2025 | Year Ended FY2024 | % Change |
| Total Income | ₹2421.454 crs | ₹2295.256 crs | 5.50% |
| Net Profit | ₹485.627 crs | ₹470.888 crs | 3.13% |
| EPS | ₹39.52 | ₹38.38 | 2.97% |
Shares of Glenmark Life Sciences Ltd was last trading in BSE at Rs. 1206.20 as compared to the previous close of Rs. 1180.60. The total number of shares traded during the day was 5887 in over 517 trades.
The stock hit an intraday high of Rs. 1224.00 and intraday low of 1173.30. The net turnover during the day was Rs. 7087451.00.
